All Brands Owned by Teva Pharmaceutical Industries

Is Teva Pharmaceutical Industries owned by another company?
No, Teva is an independent publicly traded company with no parent organization. The company is listed on the New York Stock Exchange under the ticker TEVA and is owned by institutional investors, mutual funds, and individual shareholders. No single entity holds a controlling stake.

Is Teva publicly traded?
Yes, Teva is publicly traded on the New York Stock Exchange under the ticker symbol TEVA. The company is also listed on the Tel Aviv Stock Exchange. Teva first listed on the Tel Aviv Stock Exchange in 1951 and on the NASDAQ in 1987 before moving to the NYSE.

What is Teva's annual revenue?
Teva reported FY2025 revenue of $16.5 billion, up 5% from $15.8 billion in FY2024. Non-GAAP net income was $2.3 billion with non-GAAP EPS of $2.10. The company guided for FY2026 revenue between $16.8 billion and $17.2 billion. Generic medicines accounted for approximately 70% of total revenue.

Who founded Teva?
Teva was founded in 1901 in Jerusalem by Yitzhak Elstein, Salomon Kahan, and Moshe Levinson as a wholesale drug business. The name Teva means "nature" in Hebrew. The company began manufacturing its own pharmaceutical products in the 1930s and 1940s.

What is Teva's market position?
Teva is the largest generic drug manufacturer in the world by revenue, with operations in approximately 60 countries and a portfolio of approximately 3,500 generic products. Its main competitors include Sandoz, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Viatris. Teva also markets specialty medicines including Ajovy for migraine.

How much debt does Teva have?
Teva's total debt at the end of FY2025 was approximately $15 billion, down from approximately $36 billion in 2017. The debt reduction has been achieved through asset sales, cost cuts, and operational restructuring. The debt burden originated primarily from the $40.5 billion acquisition of Actavis Generics in 2016.

What is Teva's best-selling drug?
Teva's largest specialty drug is Ajovy (fremanezumab), a preventive treatment for migraine that generated approximately $600 million in FY2025. Copaxone, once Teva's top-selling drug with peak sales of $4.2 billion, has declined to approximately $700 million due to generic competition. Teva's generic drug portfolio collectively generates the majority of revenue.